Lifeline Biotechnologies Announces New Study from Professor Kefah Mokbel That Will Test Company's First Warning System and MastaScope Products Together for Assistance in the Detection of Breast Cancer.

RENO, Nev. -- Lifeline Biotechnologies, Inc. (OTC:LBTN) today announced that Professor Kefah Mokbel, consultant breast surgeon at St. George's Hospital and Medical School and Professor at Brunel Institute of Cancer Genetics & Pharmacogenomics and his research team in the UK have commenced a new study, examining the role of mammary ductoscopy, using MastaScope, in conjunction with dynamic thermal analysis, using the First Warning System and proteomics in the early detection of breast cancer.

This study has been approved by the Ethics' Committee at St. George's Hospital Medical School in London. Participants include patients with suspected breast cancer, patients with benign breast disease, healthy volunteers and women who are known to harbor breast cancer causing genes (BRCA-1 or BRCA-2). Professor Mokbel believes that these novel strategies for breast cancer detection will complement screening mammography, which is regarded as the gold standard screening tool. Furthermore, mammary ductoscopy, using the MastaScope, may complement the role of dynamic thermal analysis in cases where these tests are positive, but anatomical imaging is negative for malignancy. This potential application may help resolve the issue of false-positive results, associated with screening tools based on physiological and biological principles. Researchers hope that if the preliminary results of this study are successful that they can be presented in the fifth European Breast Cancer Conference in France early next year.

Lifeline Biotechnologies has been in the process developing the First Warning System for a number of years and already markets the MastaScope. "We look forward to the results of Professor Mokbel's study, as this is a major step in the commercialization and introduction to the market of our First Warning System," said Jim Holmes, chairman of Lifeline.

Lifeline Biotechnologies, Inc. is a company with innovative medical technologies committed to the improvement of the quality of life through exceptional health care systems. These technologies focus on prevention, early detection, diagnosis and quick recovery of a number of disease conditions. The company's Cancer Detection technologies deal with cutting edge innovation to assist practicing physicians in the delivery of quality medical care. The MastaScope(TM) is used in the early detection of cancer and other abnormalities of the breast. The MastaScope(TM) has completed development and has entered the marketplace in the US and internationally. The First Warning System(TM) for assisting in the early detection of breast cancer and the OvaScope(TM) for assisting in the early detection of ovarian cancer are continuing to be developed by the company. More information is available at the company's website: www.lbti.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words, "believe," "expects," "projects," "forecasts," "intends," "will," "anticipated," "could," or "may," and similar conditional expressions are intended to identify forward-looking statements within the meaning of the act and are subject to the safe harbor created by the act. Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements that involve a number of risks and uncertainties.